No headlines found.
Globe Newswire (Thu, 18-Dec 8:00 AM ET)
Cocrystal Pharma to Present at the Noble Capital Markets' 21st Emerging Growth Equity Conference
Globe Newswire (Mon, 1-Dec 8:00 AM ET)
Globe Newswire (Fri, 14-Nov 8:00 AM ET)
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).
Cocrystal Pharma trades on the NASDAQ stock market under the symbol COCP.
As of February 5, 2026, COCP stock price declined to $0.86 with 185,689 million shares trading.
COCP has a beta of 0.47, meaning it tends to be less sensitive to market movements. COCP has a correlation of 0.02 to the broad based SPY ETF.
COCP has a market cap of $11.86 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, COCP traded as high as $3.29 and as low as $.86.
The top ETF exchange traded funds that COCP belongs to (by Net Assets): VTI, VXF.
COCP has underperformed the market in the last year with a price return of -56.3% while the SPY ETF gained +13.8%. COCP has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -16.5% and -17.3%, respectively, while the SPY returned +0.6% and -1.1%, respectively.
COCP support price is $.92 and resistance is $1.00 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that COCP shares will trade within this expected range on the day.
